ERBB2 and breast carcinoma: Although trastuzumab is currently approved for treatment of HER-2 overexpressing breast cancer [7] and HER-2 overexpressing metastatic gastric cancer as a result of ToGA trial [8], there are conflicting results in studies of HER-2 immunoreactivity and its relationship to prognosis on gastric cancer patients.